Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 8/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.50 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17916879 | 0.85 | HRH3 (0.68) | LSSHRH3NOTUMMCHR1LMNA | |
| SCHEMBL28085822 | 0.82 | CYP3A4 (0.62) | LSSHRH3NOTUMMCHR1JAK2 | |
| SCHEMBL6888308 | 0.80 | LSS (0.46) | LSSHRH3NOTUMMCHR1LMNA | |
| SCHEMBL3933934 | 0.80 | ADRB2 (0.59) | SIGMAR1MEN1KMT2ANOTUMLMNA | |
| Hydrochloric Acid SCHEMBL6891086 | 0.79 | LSS (0.45) | LSSHRH3NOTUMMCHR1JAK2 | |
| SCHEMBL24093308 | 0.77 | MCHR1 (0.53) | LSSHRH3NOTUMMCHR1JAK2 | |
| SCHEMBL31606050 | 0.77 | CRBN (0.40) | LSSHRH3CXCR4MCHR1JAK2 | |
| SCHEMBL27573609 | 0.76 | LSS (0.45) | LSSHRH3NOTUMMCHR1 | |
| SCHEMBL209327 | 0.76 | HPGD (0.70) | LSSHRH3CXCR4SIGMAR1MEN1 | |
| SCHEMBL1259387 | 0.75 | CXCR4 (0.81) | HRH3CXCR4SIGMAR1MEN1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111450887-A | Zinc complex synthesis and application of zinc complex as photodegradation catalyst | 盐城师范学院 | 2020-07-28 | — | — | CN | claimed |
| CN-111450887-A | Zinc complex synthesis and application of zinc complex as photodegradation catalyst | 盐城师范学院 | 2020-07-28 | — | — | CN | disclosed |
| CN-111450887-A | Zinc complex synthesis and application of zinc complex as photodegradation catalyst | 盐城师范学院 | 2020-07-28 | — | — | CN | disclosed |
| US-20090275753-A1 | ORTHO-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG | NIPPON SODA CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090275753-A1 | ORTHO-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG | NIPPON SODA CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| CN-101300243-A | O-substituted aniline derivative and antioxidant drug | NIPPON SODA CO (JP) | 2008-11-05 | — | — | CN | disclosed |
| EP-1944024-A1 | O-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG | NIPPON SODA CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275753-A1 | ORTHO-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG | NFE2L2, OXSR1, AOX1 | LSS 1905/4885HRH3 725/4885CXCR4 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.